Autolus Therapeutics (Nasdaq: AUTL) announced an abstract for the ASCO 2026 meeting reporting a post-hoc analysis of the Phase Ib/II FELIX study of obe-cel in adult relapsed/refractory B-ALL, including patients with extramedullary disease (EMD).
Of 127 obe-cel–infused patients, 27 (21%) had EMD at lymphodepletion. In patients with EMD, the overall remission rate was 59% and median duration of response was 42.6 months, supporting a favorable benefit–risk profile.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – AUTL
+3.03%
7 alerts
+3.03%Session close to close
+2.9%Peak in 28 hr 28 min
$465.77MMarket Cap
0.1xRel. Volume
In the May 22 session, AUTL gained 3.03%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +2.9% during that session.
Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
This announcement adds a focused FELIX subgroup analysis, showing a 59% overall response rate and 42...
Analysis
This announcement adds a focused FELIX subgroup analysis, showing a 59% overall response rate and 42.6-month median duration of response in B-ALL patients with extramedullary disease, a traditionally high‑risk group. It builds on prior obe-cel data across hematology and autoimmune indications. Investors may track subsequent full-data presentations, future FELIX updates, and any capital raises under the $150,000,000 shelf as the program and balance sheet evolve.
Key Figures
Overall response rate:59%Median duration of response:42.6 monthsPatients infused:127 patients+5 more
8 metrics
Overall response rate59%FELIX post-hoc EMD subgroup in r/r B-ALL
Median duration of response42.6 monthsResponders with extramedullary disease at lymphodepletion
Patients infused127 patientsTotal FELIX obe-cel infused population
Patients with EMD27 patients (21%)Had extramedullary disease at lymphodepletion
ASCO meeting datesMay 29–June 2, 2026ASCO Annual Meeting 2026 in Chicago
EHA FELIX data showing durable remissions and low high-grade CRS/ICANS.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Clinical updates have often been positive fundamentally but produced mixed price reactions, with several notable divergences on ostensibly good data.
Recent Company History
Over the past year, Autolus has repeatedly highlighted obe-cel’s clinical profile across autoimmune and oncology settings. Updates from CARLYSLE in severe lupus and EHA/ASH FELIX data in B-ALL showed encouraging remission and safety signals, while new trials such as BOBCAT in progressive MS expanded the program’s reach. Price reactions were mixed, with both gains and selloffs around these data. The current ASCO abstract on FELIX patients with EMD fits this pattern of incremental, indication-broadening clinical disclosure.
Key Terms
extramedullary disease, overall response rate, median duration of response, post-hoc analysis, +4 more
8 terms
extramedullary diseasemedical
"obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically"
Extramedullary disease means cancer cells have spread and are growing outside the bone marrow, where certain blood cancers normally live. Like weeds appearing beyond a fenced garden, this spread can make the disease harder to treat, change which medicines or procedures are needed, and affect outcomes, clinical trial results, and costs—information investors watch because it can influence a company’s revenue, regulatory decisions, and stock value.
overall response ratemedical
"With an overall response rate of 59% and a median duration of response (mDOR)"
Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.
median duration of responsemedical
"an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months"
Median duration of response is the midpoint time that a beneficial effect from a treatment lasts among patients who showed a measurable improvement; half of responders saw the effect stop sooner, half later. Investors care because it shows how durable a therapy’s benefit is — like the typical lifespan of a product’s performance — which affects expected clinical value, market demand, pricing power and reimbursement prospects.
post-hoc analysismedical
"Summary: A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660)"
Post-hoc analysis is an examination of data carried out after an experiment, trial, or reporting period to look for patterns or explanations that were not specified beforehand. It matters to investors because such findings can suggest new opportunities or risks but are more likely to be chance results than preplanned conclusions, so they require independent confirmation before being treated as reliable — like noticing a pattern on a map after a trip and then testing it on the next journey.
phase ib/iimedical
"A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted"
Phase Ib/II is a combined clinical trial stage where a drug is first tested in small groups to find a safe and tolerable dose (Phase Ib) and then that dose is given to more patients to look for early signs it works (Phase II). For investors, progression through these steps reduces scientific risk and creates clear milestones—like moving from kitchen taste-tests to a limited restaurant trial—that can materially change a company’s value.
lymphodepletionmedical
"by EMD status at lymphodepletion (LD). Following LD, adults with r/r B-ALL"
Lymphodepletion is a short medical treatment that lowers a patient’s lymphocytes, the immune cells that can interfere with certain cell-based therapies, to create a more supportive environment for the new therapy to work. Think of it like clearing a crowded garden bed before planting seeds: by temporarily reducing competing cells, the engineered therapy can take hold more effectively. Investors watch lymphodepletion because it affects clinical trial results, safety profiles, treatment adoption, and overall commercial potential.
b-cell acute lymphoblastic leukemiamedical
"obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia"
A fast-growing blood cancer in which immature B cells — a type of white blood cell that helps fight infection — multiply in the bone marrow and spill into the bloodstream, crowding out healthy cells and impairing immunity. Investors pay attention because its diagnosis, treatment advances, clinical-trial results and regulatory approvals can quickly change demand for drugs, company valuations, and the costs borne by healthcare systems, much like a sudden shift in product demand reshapes a market.
car tmedical
"next-generation programmed T cell therapies and candidates, announces the online"
CAR T is a type of immunotherapy that reprograms a patient’s own white blood cells to recognize and attack cancer cells, like giving immune cells a custom GPS to find and destroy tumors. It matters to investors because CAR T therapies can offer durable responses for hard-to-treat cancers, but they also involve complex manufacturing, high costs, regulatory hurdles and market access challenges that affect a company’s revenue potential and risk profile.
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.
“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a potential treatment option for this difficult to treat population of patients,” said Matthias Will, MD, Autolus Chief Development Officer.
Abstract 6517 Title: The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD). Session Type and Track: Rapid Oral Abstract: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. Session Date and Time: May 30, 2026; 1:15 – 2:45PM CDT Session Room: E450a Abstract Number: 6517 Presentation time: 2:27 – 2:33pm CDT Presenting Author: Jae Park, MD, Director, Adult ALL Program | Acting Chief, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Summary: A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted, evaluating the efficacy and safety of obe-cel in patients with relapsed or refractory (r/r) B-ALL, by EMD status at lymphodepletion (LD). Following LD, adults with r/r B-ALL received obe-cel using a tumor burden-guided dosing strategy to minimize toxicity. Obe-cel treatment demonstrated favorable response and safety outcomes in patients with and without EMD in the FELIX trial. Of 127 obe-cel infused patients, 27 (21%) had EMD at LD. Among responders, duration of response in patients with EMD was 42.6 months, and the overall remission rate was 59%. Overall, these findings suggest a positive benefit–risk profile for obe-cel, including for patients with adverse risk features, specifically EMD at LD.
About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
What clinical data on obe-cel will Autolus Therapeutics (AUTL) present at ASCO 2026?
Autolus will present a post-hoc analysis from the Phase Ib/II FELIX trial of obe-cel in adult relapsed/refractory B-ALL, including patients with extramedullary disease. According to Autolus, the analysis evaluates efficacy and safety by EMD status at lymphodepletion using a tumor burden-guided dosing strategy.
How did obe-cel perform in B-ALL patients with extramedullary disease in the FELIX study of AUTL?
Obe-cel showed a 59% overall remission rate and 42.6-month median duration of response in patients with extramedullary disease. According to Autolus, these patients represented 27 of 127 infused (21%) and outcomes supported a positive benefit–risk profile, including for those with adverse risk features.
When and where is Autolus Therapeutics (AUTL) presenting its FELIX trial data at ASCO 2026?
The obe-cel data will be presented May 30, 2026, from 2:27–2:33 p.m. CDT at ASCO 2026 in Chicago. According to Autolus, this is Rapid Oral Abstract 6517 in Session E450a, covering hematologic malignancies including leukemia and related disorders.
What is Abstract 6517 about for Autolus Therapeutics (AUTL) at ASCO 2026?
Abstract 6517 examines the effect of obe-cel in adult relapsed/refractory B-cell acute lymphoblastic leukemia with and without extramedullary disease. According to Autolus, it is a post-hoc analysis of the FELIX trial assessing efficacy and safety by EMD status at lymphodepletion.
What dosing strategy for obe-cel was used in the FELIX trial data presented by AUTL?
The FELIX study used a tumor burden-guided dosing strategy for obe-cel after lymphodepletion. According to Autolus, this approach was intended to minimize toxicity while treating adults with relapsed or refractory B-ALL, including those with extramedullary disease at lymphodepletion.
What does the Autolus Therapeutics (AUTL) ASCO 2026 update suggest about obe-cel’s benefit–risk profile?
The update suggests a positive benefit–risk profile for obe-cel in adults with relapsed/refractory B-ALL, including those with extramedullary disease. According to Autolus, obe-cel treatment showed favorable response and safety outcomes in FELIX patients with and without EMD at lymphodepletion.
